Low-dose carboplatin modifies the tumor microenvironment to augment CAR T cell efficacy in human prostate cancer models

L. H. Porter, J. J. Zhu, N. L. Lister, S. G. Harrison, S. Keerthikumar, D. L. Goode, R. Quezada Urban, D. J. Byrne, A. Azad, I. Vela, M. S. Hofman, P. J. Neeson, P. K. Darcy, J. A. Trapani, R. A. Taylor () and G. P. Risbridger ()
Additional contact information
L. H. Porter: Monash University
J. J. Zhu: Peter MacCallum Cancer Centre
N. L. Lister: Monash University
S. G. Harrison: Monash University
S. Keerthikumar: The University of Melbourne
D. L. Goode: The University of Melbourne
R. Quezada Urban: The University of Melbourne
D. J. Byrne: Peter MacCallum Cancer Centre
A. Azad: The University of Melbourne
I. Vela: Queensland University of Technology
M. S. Hofman: The University of Melbourne
P. J. Neeson: Peter MacCallum Cancer Centre
P. K. Darcy: Peter MacCallum Cancer Centre
J. A. Trapani: Peter MacCallum Cancer Centre
R. A. Taylor: Peter MacCallum Cancer Centre
G. P. Risbridger: Monash University

Nature Communications, 2023, vol. 14, issue 1, 1-17

Abstract: Abstract Chimeric antigen receptor (CAR) T cells have transformed the treatment landscape for hematological malignancies. However, CAR T cells are less efficient against solid tumors, largely due to poor infiltration resulting from the immunosuppressive nature of the tumor microenvironment (TME). Here, we assessed the efficacy of Lewis Y antigen (LeY)-specific CAR T cells in patient-derived xenograft (PDX) models of prostate cancer. In vitro, LeY CAR T cells directly killed organoids derived from androgen receptor (AR)-positive or AR-null PDXs. In vivo, although LeY CAR T cells alone did not reduce tumor growth, a single prior dose of carboplatin reduced tumor burden. Carboplatin had a pro-inflammatory effect on the TME that facilitated early and durable CAR T cell infiltration, including an altered cancer-associated fibroblast phenotype, enhanced extracellular matrix degradation and re-oriented M1 macrophage differentiation. In a PDX less sensitive to carboplatin, CAR T cell infiltration was dampened; however, a reduction in tumor burden was still observed with increased T cell activation. These findings indicate that carboplatin improves the efficacy of CAR T cell treatment, with the extent of the response dependent on changes induced within the TME.

Date: 2023
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-023-40852-3 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-40852-3

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-023-40852-3

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().